Xeris Pharmaceuticals doses first patient in phase 2 trial to assess ready-to-use glucagon

Image: The phase 2 study will evaluate Xeris’ ready-to-use glucagon as a pre-treatment to prevent exercise-induced hypoglycemia in 48 patients with type 1 diabetes. Photo: courtesy of renjith Krishnan / FreeDigitalPhotos.net.